AbbVie Inc. Tax Policy: FDII, GILTI, and Effective Rate

AbbVie’s federal tax picture is shaped by two laws and a shifting international framework. The Tax Cuts and Jobs Act of 2017 permanently lowered the corporate rate from 35 percent to 21 percent and moved the United States to a modified territorial system. The One Big Beautiful Bill Act of 2025 restored immediate expensing for domestic research costs, locked in a lower effective rate on export-related intellectual property income, and brought back 100 percent bonus depreciation.¹ Against that backdrop, AbbVie has reported a GAAP effective tax rate around 31 to 33 percent and an adjusted rate close to 15 percent in recent quarters, so AbbVie’s tax policy changes and effective rates diverge sharply depending on which measure you read.²

The 21 Percent Rate and Territorial Baseline

The Tax Cuts and Jobs Act cut the top federal corporate rate to 21 percent and, unlike much of the individual side of that law, made the reduction permanent. AbbVie has used 21 percent as the starting point for its federal tax calculations every year since.

The same law replaced worldwide taxation with a modified territorial approach. Dividends AbbVie receives from foreign subsidiaries in which it holds at least a 10 percent stake are generally exempt from additional U.S. tax. That removed the incentive to keep overseas cash overseas, and it framed the way AbbVie has redeployed foreign earnings since 2018.

What the 2025 Law Changed

Public Law 119-21 was signed on July 4, 2025. Three provisions matter most for a pharmaceutical company on AbbVie’s scale: the restoration of immediate deduction of domestic research costs, the preservation of the foreign-derived intangible income deduction at a fixed level, and the return of 100 percent bonus depreciation for qualifying property placed in service after January 19, 2025.¹ In its second-quarter 2025 filing, AbbVie said it was “currently evaluating the impact of the 2025 Act on its consolidated financial statements.”³

Domestic R&D Expensing Under Section 174

From 2022 through 2024, the tax code required companies to spread domestic research costs over five years rather than deducting them in the year spent. For AbbVie, which spent roughly $4.2 billion on R&D in just the first half of 2025, that amortization requirement inflated near-term taxable income and delayed the full tax benefit of each research dollar.³

The 2025 law reversed the requirement for tax years beginning after December 31, 2024. Domestic research and experimental costs can once again be deducted in full in the year incurred, with an option to capitalize and amortize over at least 60 months if a company prefers.¹ Foreign research costs still follow the old rule: mandatory capitalization and amortization over 15 years.⁴ That split creates a meaningful tax incentive to locate research inside the United States.

The FDII Deduction on Export IP Income

Section 250 lets domestic corporations deduct a percentage of their foreign-derived intangible income, which broadly covers profits from selling goods or licensing IP to foreign buyers above a routine return on tangible assets. For a company whose international revenue depends on patented therapies, this is a significant lever.

The original deduction was 37.5 percent of qualifying income, producing an effective rate of about 13.125 percent. A scheduled reduction would have cut the deduction to 21.875 percent starting in 2026, raising the effective rate to roughly 16.4 percent. The 2025 law eliminated that scheduled reduction and set the deduction at 33.34 percent going forward, translating to an effective rate near 14 percent on qualifying income.⁵ The deduction applies only to C corporations, and the income must come from sales or services to foreign persons for foreign use.

The 15 Percent Corporate Minimum Tax

The Inflation Reduction Act of 2022 reintroduced a corporate minimum tax targeted at large companies that report substantial book profits while paying relatively little federal income tax. The corporate alternative minimum tax imposes 15 percent on adjusted financial statement income, essentially book net income with certain modifications.⁶

The tax applies only to corporations whose average annual adjusted financial statement income exceeds $1 billion over the prior three tax years.⁷ AbbVie clears that threshold. The company owes CAMT only to the extent that 15 percent of adjusted financial statement income exceeds its regular tax liability plus any base erosion minimum tax. In years when the regular tax bill already exceeds the CAMT calculation, the minimum tax adds nothing.

Interest Deduction Cap After the Allergan Deal

AbbVie took on significant debt to fund its $63 billion acquisition of Allergan in 2020, and Section 163(j) governs how much of the resulting interest expense is deductible. Business interest deductions are capped at the sum of business interest income plus 30 percent of adjusted taxable income for the year, and adjusted taxable income is calculated without regard to depreciation, amortization, or depletion.⁸ Interest above the cap carries forward rather than being lost permanently. As AbbVie pays down acquisition-related principal, the 163(j) limit becomes less binding.

International Layer: Pillar Two, Ireland, and GILTI

AbbVie’s substantial operations in Ireland sit inside two overlapping international frameworks.

The U.S. Pillar Two Exemption

The OECD’s Global Anti-Base Erosion Rules establish a 15 percent minimum effective tax rate for multinationals with consolidated revenue above €750 million, with a top-up tax closing any gap.⁹ The United States has not implemented Pillar Two domestically. In early 2026, the U.S. Treasury announced an agreement within the OECD framework to exempt U.S.-headquartered companies from Pillar Two, leaving them subject only to U.S. global minimum taxes.¹⁰

Ireland’s 15 Percent Floor

The exemption does not reach Ireland’s own law. Ireland transposed the EU Pillar Two directive and introduced a Qualified Domestic Minimum Top-Up Tax for fiscal years beginning on or after December 31, 2023, bringing the effective rate to 15 percent for in-scope companies.¹¹ Ireland’s standard trading rate of 12.5 percent still applies to businesses outside that scope.¹² AbbVie’s revenue puts it well above the €750 million threshold, so its Irish operations now face a 15 percent floor rather than 12.5 percent.

GILTI on Foreign IP Earnings

The TCJA’s GILTI rules require U.S. shareholders of foreign subsidiaries to include in taxable income any earnings that exceed a 10 percent deemed return on the subsidiary’s tangible assets.¹³ For a company whose most valuable assets are drug patents, GILTI captures a large share of foreign earnings. Taxes paid to Ireland under the top-up regime may generate credits that offset the U.S. GILTI inclusion, though the net effect depends on the jurisdictional mix of earnings in a given year.

The Effective Rate AbbVie Actually Reports

The provisions above combine to produce an effective rate that often looks nothing like 21 percent. In the first quarter of 2026, AbbVie reported a GAAP effective tax rate of 32.9 percent and an adjusted rate of 15.4 percent.² The wide gap reflects items like changes in the fair value of contingent consideration from acquisitions, which inflate GAAP tax rates without affecting the core operating tax picture. The adjusted rate sits below the statutory rate primarily because of lower tax rates on foreign earnings and the FDII deduction on export-related profits.

For the first half of 2025, the GAAP effective rate was 31 percent, up from 30 percent in the same period of 2024. AbbVie attributed the increase largely to changes in fair value of contingent consideration, offset partially by a more favorable mix of earnings across jurisdictions.³ The reported rate in any quarter can swing significantly on non-cash items unrelated to the drug business itself.

Where the Tax Savings Go

Capital freed by favorable tax treatment moves into three channels: shareholder returns, debt reduction, and reinvestment.

AbbVie has increased its quarterly dividend every year since becoming an independent company. In one notable move, the board raised the quarterly dividend by 35 percent, from $0.71 to $0.96 per share, while authorizing a new $10 billion stock repurchase program.¹⁴

Debt paydown has mattered just as much. Reducing Allergan-related principal improves the credit profile, lowers interest cost, and eases the Section 163(j) constraint. The remaining capital flows into manufacturing infrastructure, pipeline acquisitions, and the R&D spending that once again benefits from immediate expensing under the amended Section 174.

1
Internal Revenue Service. One, Big, Beautiful Bill Provisions
2
AbbVie. AbbVie Reports First-Quarter 2026 Financial Results
3
AbbVie. Form 10-Q for the Period Ended June 30, 2025
4
Office of the Law Revision Counsel. 26 U.S. Code 174 – Amortization of Research and Experimental Expenditures
5
Office of the Law Revision Counsel. 26 USC 250 – Deduction for Foreign-Derived Intangible Income and Global Intangible Low-Taxed Income
6
Office of the Law Revision Counsel. 26 USC 55 – Alternative Minimum Tax Imposed
7
Internal Revenue Service. Instructions for Form 4626 (2025)
8
Office of the Law Revision Counsel. 26 U.S. Code 163 – Interest
9
Organisation for Economic Co-operation and Development. Global Anti-Base Erosion Model Rules (Pillar Two)
10
U.S. Department of the Treasury. Treasury Secures Agreement to Exempt U.S.-Headquartered Companies
11
Department of Finance. Minister McGrath Notes Ireland’s Application of Effective 15% Corporation Tax Rate for In-Scope Businesses
12
Revenue Irish Tax and Customs. Corporation Tax for Companies – Basis of Charge
13
Internal Revenue Service. Concepts of Global Intangible Low-Taxed Income Under IRC 951A
14
AbbVie. AbbVie Increases Dividend and Announces New Stock Repurchase Program